These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1489 related articles for article (PubMed ID: 30898152)

  • 1. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
    Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
    Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
    Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
    Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.
    Cruz-Lozano M; González-González A; Marchal JA; Muñoz-Muela E; Molina MP; Cara FE; Brown AM; García-Rivas G; Hernández-Brenes C; Lorente JA; Sanchez-Rovira P; Chang JC; Granados-Principal S
    Eur J Nutr; 2019 Dec; 58(8):3207-3219. PubMed ID: 30460610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
    Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
    Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME
    Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
    BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.
    Tan EJ; Olsson AK; Moustakas A
    Cell Adh Migr; 2015; 9(3):233-46. PubMed ID: 25482613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.
    Zhang Y; Chen J; Mi D; Ling J; Li H; He P; Liu N; Chen Q; Chen Y; Huang L
    Cancer Lett; 2023 Apr; 560():216142. PubMed ID: 36965539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
    González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
    Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.